Transforming growth factor β mimetics: Discovery of 7-[4-(4-cyanophenyl) phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase

Molecular Cancer Therapeutics

Volumn 1, Issue 10, 2002, Pages 759-768

  Glaser, Keith B ^a   Li, Junling ^a   Aakre, Mary E ^b   Morgan, Douglas W ^a   Sheppard, George ^a   Stewart, Kent D ^a   Pollock, Jennifer ^a   Lee, Paul ^a   O'Connor, Chad Z ^a   Anderson, Steven N ^a   Mussatto, Donna J ^a   Wegner, Craig W ^a   Moses, Harold L ^b  

^a ABBOTT LABORATORIES   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 (4 (4 CYANOPHENYL)PHENOXY)HEPTANOHYDROXAMIC ACID; 7-(4-(4-CYANOPHENYL)PHENOXY)HEPTANOHYDROXAMIC ACID; BIPHENYL DERIVATIVE; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; COLLAGENASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; FIBRONECTIN; GELSOLIN; HISTONE DEACETYLASE; HYDROXAMIC ACID; LUCIFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA;

ACETYLATION; ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIVISION; CELL LINE; CHEMICAL MODEL; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; EPITHELIUM CELL; FIBROBLAST; GENETIC TRANSFECTION; GENETICS; HUMAN; IC 50; KERATINOCYTE; LUNG; METABOLISM; MINK; MOUSE; PHENOTYPE; PROMOTER REGION; TIME; WESTERN BLOTTING;

ACETYLATION; ANIMALS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL LINE; COLLAGENASES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPITHELIAL CELLS; FIBROBLASTS; FIBRONECTINS; G1 PHASE; GELSOLIN; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; KERATINOCYTES; LUCIFERASES; LUNG; MICE; MINK; MODELS, CHEMICAL; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS (GENETICS); S PHASE; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0036689042     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Alexandrow, M., and Moses, H. Transforming growth factor β and cell cycle regulation. Cancer Res., 55: 1452-1457, 1995.
2. Heldin, C-H., Miyazono, K., and ten Dijke, P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature (Lond.), 390: 465-471, 1997. (Pubitemid 28013118)
3. Massague, J., and Wotton, D. Transcriptional control of the TGF-β/Smad signaling system. EMBO J., 19: 1745-1754, 2000. (Pubitemid 30204386)
4. Massague, J. The transforming growth factor β family. Annu. Rev. Cell Biol., 6: 597-641, 1990.
5. Yuan, W., and Varga, J., Transforming growth factor β repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J. Biol. Chem., 276: 38502-38510, 2001.
6. Sporn, M., Roberts, A., Wakefield, L., and deCrombrugghe, B. Some recent advances in the chemistry and biology of transforming growth factor β. J. Cell Biol., 105: 1039-1045, 1987. (Pubitemid 18029829)
7. Roberts, A., and Sporn, M. Physiological actions and clinical applications of transforming growth factor β (TGF-β). Growth Factors, 8: 1-9, 1993. (Pubitemid 23093206)
8. Massague, J., Blain, S., and Lo, R. TGF-β signaling in growth control, cancer, and heritable disorders. Cell, 103: 295-309, 2000.
9. Derynck, R. TGF-β-receptor-mediated signaling. Trends Biochem. Sci., 19: 548-553, 1994.
10. Wotton, D., Lo, R., Lee, S., and Massague, J. A Smad transcriptional corepressor. Cell, 97: 29-39, 1999. (Pubitemid 29165887)
11. Derynck, R., Zhang, Y., and Feng, X-H. Smads: transcriptional activators of TGF-β responses. Cell, 95: 737-740, 1998. (Pubitemid 29014453)
12. Akiyama, Y., Iwanaga, R., Ishikawa, T., Sakamoto, K., Nishi, N., Nihei, Z., Iwama, T., Saitoh, K., and Yuasa, Y. Mutations of the transforming growth factor β type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability. Cancer (Phila.), 78: 2478-2484, 1996. (Pubitemid 26415678)
13. Vincent, F., Nagashima, M., Takenoshita, S., Khan, M., Gemma, A., Hagiwara, K., and Bennett, W. Mutation analysis of the transforming growth factor β type II receptor in human cell lines resistant to growth inhibition by transforming growth factor β. Oncogene, 15: 117-122, 1997. (Pubitemid 27348103)
14. Zhang, T., Nanney, L., Peeler, M., Williams, C., Lamps, L., Heppner, K., DuBois, R., and Beauchamp, R. Decreased transforming growth factor β type II receptor expression in intestinal adenoma from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Cancer Res., 57: 1638-1643, 1997. (Pubitemid 27199650)
15. Grady, W., Rajput, A., Myeroff, L., Liu, D., Kwon, K., Willis, J., and Markowitz, S. Mutation of the type II transforming growth factor β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res., 58: 3101-3104, 1998. (Pubitemid 28335093)
16. Venkatasubbarao, K., Ammanamanchi, S., Brattain, M., Mimari, D., and Freeman, J. Reversion of transcriptional repression of Sp1 by 5 aza-2′ deoxycytidine restores TGF-β type II receptor expression in the pancreatic cancer cell line MIA PaCa-2. Cancer Res., 61: 6239-6247, 2001. (Pubitemid 32762563)
17. Lee, B., Park, S., Kim, J., Sausville, E., Kim, H., Nakanishi, O., Trepel, J., and Kim, S. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor β type II receptor expression in human breast cancer cells. Cancer Res., 61: 931-934, 2001. (Pubitemid 32174406)
18. ten Dijke, P., Miyazono, K., and Heldin, C-H., Signaling inputs converge on nuclear effectors in TGF-β signaling. Trends Biochem. Sci., 25: 64-70, 2000. (Pubitemid 30100368)
19. Abe, M., Harpel, J., Metz, C., Nunes, I., Loskutoff, D., and Rifkin, D. An assay for transforming growth factor β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem., 216: 276-284, 1994. (Pubitemid 24076008)
20. Yoshida, M., Kijima, M., Akita, M., and Beppu, T., Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 265: 17174-17179, 1990.
21. Tian, S-S., Lamb, P., King, A., Miller, S., Kessler, L., Luengo, J., Averill, L., Johnson, R., Gleason, J., Pelus, L., Dillon, S., and Rosen, J. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science (Wash. DC), 281: 257-259, 1998. (Pubitemid 28334508)
22. Su, G., Sohn, T., Rhyu, B., and Kern, S. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res., 60: 3137-3142, 2000. (Pubitemid 30407906)
23. Masuoka, Y., Shin-Ya, K., Kim, Y-B., Yoshida, M., Nagi, K., and Suzuki, K-I. Diheteropeptin, a novel substance with TGF-β activity, produced by a fungus Diherospora chlamydosporia. J. Antibiot. (Tokyo), 53: 788-792, 2000.
24. Hartsough, M., and Mulder, K. Transforming growth factor β signaling in epithelial cells. Pharmacol. Ther., 75: 21-41, 1997. (Pubitemid 27444685)
25. Moustakas, A., and Kardassis, D., Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc. Natl. Acad. Sci. USA, 95: 6733-6738, 1998. (Pubitemid 28278049)
26. Liu, X., Sun, Y., Weinberg, R., and Lodish, H. Ski/Sno and TGF-β signaling. Cytokine Growth Factor Rev., 12: 1-8, 2001.
27. Richon, V., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkin, R., and Marks, P. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA, 95: 3003-3007, 1998. (Pubitemid 28135844)
28. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. A synthetic inhibitor of histone deacetylase. MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA, 96: 4592-4597, 1999. (Pubitemid 29190381)
29. Chaponnier, C., and Gabbiani, G. Gelsolin modulation in epithelial and stromal cells of mammary carcinoma. Am. J. Pathol., 134: 597-603, 1989. (Pubitemid 19082853)
30. Vandekerckhove, J., Bauw, G., Vancompernolle, K., Honore, B., and Celis, J. Comparative two-dimensional gel analysis and microsequencing identifies gelsolin as one of the most prominent down-regulated markers of transformed human fibroblast and epithelial cells. J. Cell Biol., 111: 95-102, 1990.
31. Hoshikawa, Y., Kwon, H., Yoshida, M., Horinouchi, S., and Beppu, T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp. Cell Res., 214: 189-197, 1994. (Pubitemid 24302392)
32. Glaser, K., Li, J., Morgan, D., Sheppard, G., Stewart, K., Pollock, J., Lee, P., O'Connor, C., Anderson, S., Mussatto, D., Wegner, C., Aaker, M., and Moses, H. Biaryl hydroxamates: small molecule TGF-β mimetics. Proc. Am. Assoc. Cancer Res., 39: 175, 1998.
33. Yoshida, M., Hoshikawa, Y., Koseki, K., Mori, K., and Beppu, T. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J. Antibiot. (Tokyo), 43: 1101-1106, 1990. (Pubitemid 20324373)
34. Stroschein, S., Wang, W., Zhou, S., Zhou, Q., and Luo, K. Negative feedback regulation of TGF-β signaling by the SnoN oncoprotein. Science (Wash. DC), 286: 771-774, 1999.
35. Warrell, R., He, L-Z., Richon, V., Calleja, E., and Pandolfi, P., Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. (Bethesda), 90: 1621-1625, 1998. (Pubitemid 28523436)
36. Masuoka, Y., Nagai, A., Shin-ya, K., Furihata, K., Nagai, K., Suzuki, K-I., Hayakawa, Y., and Seto, H. Spiruchostatin A and B, novel gene expression-enhancing substances produced by Pseudomonas sp. l. Tetrahedron Lett., 42: 41-44, 2001. (Pubitemid 32011701)
37. Masuoka, Y., Shin-Ya, K., Furihata, K., Hayakawa, Y., and Seto, H. A novel substance with TGF-β like activity, diheteropeptin, produced by a fungus, Diheterospora sp. J. Antibiot. (Tokyo), 50: 1058-1060, 1997. (Pubitemid 28045940)
38. Nakajima, H., Kim, Y., Terano, H., Yoshida, M., and Horinouchi, S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res., 241: 126-133, 1998. (Pubitemid 28366586)
39. Sohn, T., Su, G., Ryu, B., Yeo, C., and Kern, S., High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells. Ann. Surg., 233: 696-703, 2001. (Pubitemid 32378654)
40. Finnin, M., Donigian, J., Cohen, A., Richon, V., Rifkind, R., Marks, P., Breslow, R., and Pavletich, N. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (Lond.), 401: 188-193, 1999. (Pubitemid 29436325)
41. Muro-Cacho, C., Rosario-Ortiz, K., Livingston, S., and Munoz-Antonia, T. Defective transforming growth factor β signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2. Clin. Cancer Res., 7: 1618-1626, 2001. (Pubitemid 32708627)